Evidence map›Paper›PMID 42282497›Full record

ArticleJournal of surgical case reports2026

Consolidative cystectomy after complete response to enfortumab vedotin plus pembrolizumab in metastatic bladder cancer: a case report.

Romain Lefranc, Clémentine Mathieu, Achraf Ghorbel, Alexandre Léger-Vigot, Xavier Tillou, Thibaut Waeckel

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Romain LefrancUrology Department, CHU de Caen, avenue de la Côte de Nacre, 14000 Caen, France.ORCID https://orcid.org/0009-0007-6296-5077
Clémentine MathieuUrology Department, CHU de Caen, avenue de la Côte de Nacre, 14000 Caen, France.
Achraf GhorbelOncology Department, CHU de Caen, avenue de la Côte de Nacre, 14000 Caen, France.
Alexandre Léger-VigotPathology Department, CHU de Caen, avenue de la Côte de Nacre, 14000 Caen, France.
Xavier TillouUrology Department, CHU de Caen, avenue de la Côte de Nacre, 14000 Caen, France.
Thibaut WaeckelUrology Department, CHU de Caen, avenue de la Côte de Nacre, 14000 Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic muscle-invasive bladder cancer carries a poor prognosis despite recent therapeutic advances. Enfortumab vedotin plus pembrolizumab (EVP) is now the standard first-line treatment for metastatic urothelial carcinoma. However, the role of local consolidative treatment after deep systemic response remains undefined. We report the case of a 59-year-old man with

Indexed as

bladder cancerconsolidative surgeryenfortumab vedotinmetastatic diseasepathological complete responsepembrolizumab

Identifiers

PMID42282497
PMCPMC13250332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.